Trimel to Report Third Quarter 2014 Results and Host Conference Call to Update Investors
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 10/29/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) will report its third quarter financial results for the period ended September 30, 2014 on Thursday, November 6, 2014 before markets open.
Management of the Company will host a conference call to discuss these results and update investors on the status of its business on Friday, November 7, 2014 at 8:30 a.m. Eastern Standard Time. Following the discussion, Trimel executives will address inquiries from investment analysts.
To access the call live, please dial 416-340-2216 or 1-866-223-7781. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.
A replay of the conference call will be available until 7:00 p.m. Eastern Standard Time on Friday, November 14, 2014 by dialing 905-694-9451 or 1-800-408-3053, using access code: 3455434#.
For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at 416-679-0536 or via email at .
About Trimel
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. Natesto™, a product utilizing Trimel's licensed bioadhesive nasal gel technology, has been approved for sale in the United States by the FDA. For more information, please visit .
Contacts:
Trimel Pharmaceuticals Corporation
Kenneth G. Howling
Chief Financial Officer
416 679 0536
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.10.2014 - 21:05 Uhr
Sprache: Deutsch
News-ID 348120
Anzahl Zeichen: 0
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 164 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Trimel to Report Third Quarter 2014 Results and Host Conference Call to Update Investors"
steht unter der journalistisch-redaktionellen Verantwortung von
Trimel Pharmaceuticals Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
